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Abstract
We aimed to compare [18F]-florbetaben PET imaging in four transgenic mouse strains
modelling Alzheimer’s disease (AD), with the main focus on APPswe/PS2 mice and C57Bl/
6 mice serving as controls (WT). A consistent PET protocol (N = 82 PET scans) was used,
with cortical standardized uptake value ratio (SUVR) relative to cerebellum as the endpoint.
We correlated methoxy-X04 staining of β-amyloid with PET results, and undertook ex vivo
autoradiography for further validation of a partial volume effect correction (PVEC) of PET
data. The SUVR in APPswe/PS2 increased from 0.95±0.04 at five months (N = 5) and
1.04±0.03 (p<0.05) at eight months (N = 7) to 1.07±0.04 (p<0.005) at ten months (N = 6),
1.28±0.06 (p<0.001) at 16 months (N = 6) and 1.39±0.09 (p<0.001) at 19 months (N = 6).
SUVR was 0.95±0.03 in WTmice of all ages (N = 22). In APPswe/PS1G384A mice, the
SUVR was 0.93/0.98 at five months (N = 2) and 1.11 at 16 months (N = 1). In APPswe/
PS1dE9 mice, the SUVR declined from 0.96/0.96 at 12 months (N = 2) to 0.91/0.92 at 24
months (N = 2), due to β-amyloid plaques in cerebellum. PVEC reduced the discrepancy
between SUVR-PET and autoradiography from −22% to +2% and increased the differences
between young and aged transgenic animals. SUVR and plaque load correlated highly be-
tween strains for uncorrected (R = 0.94, p<0.001) and PVE-corrected (R = 0.95, p<0.001)
data. We find that APPswe/PS2 mice may be optimal for longitudinal amyloid-PET monitor-
ing in planned interventions studies.
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Introduction
The steadily growing number of patients suffering from Alzheimer’s disease (AD) will place a
great burden on healthcare systems in the coming decades, baring development of an effective
intervention therapy [1]. Molecular imaging of β-amyloid with positron emission tomography
(PET) has given new insight into the progression of AD pathology and has entered clinical
diagnostic use [2]. Furthermore, PET imaging is increasingly used for detecting cerebral amy-
loidosis in transgenic mouse models of AD [3,4]. Small animal PET studies of longitudinal
design afford monitoring of the rate of β-amyloid accumulation, and present the possibility of
testing interventions for attenuating plaque formation. However, there are some controversies
in the literature with regard to the fitness of amyloid-imaging in different AD-mouse models.
For example, one PET study failed to reveal any specific signal [5], and another did not detect
the known increase of β-amyloid in an aging AD mouse model [6]. Other investigations suc-
cessfully monitored the progression of amyloidosis in APP23 mice [7] or the early onset of
amyloidosis in 5xFAD mice [8]. Comparisons between recent small animal β-amyloid PET
studies are difficult, due to the diversity of mouse models, radiotracers, imaging protocols, and
quantification strategies [9]. Hence, we wanted to undertake a PET study with an established
β-amyloid tracer in several AD mouse strains, applying standardized methods, and correlating
PET findings with histological analysis. We therefore aimed to make PET recordings with the
[18F]-labelled β-amyloid tracer florbetaben [10–12] in four different AD mouse models at a
range of ages, with the main focus on APPswe/PS2 mice. Our additional objective was to gener-
alize our validation of partial volume effect correction (PVEC) for quantitation of β-amyloid
burden in APPswe mice [13] for APPswe/PS2 mice. Furthermore, we conducted a comprehen-
sive search of the existing literature in order to review systematically the several AD mouse
models investigated by florbetaben and other PET tracers for β-amyloid.
Materials and Methods
2.1 Animal models
All experiments were performed in compliance with the National Guidelines for Animal Pro-
tection, Germany, with approval of the local animal care committee of the Government of
Oberbayern (Regierung Oberbayern), and overseen by a veterinarian. Anaesthesia was per-
formed with isoflurane 1.5%. Euthanasia was performed in deep narcosis by cervical disloca-
tion. Three newly explored and one previously described [3] AD mouse models were assessed
by PET at different ages, and ultimately by autoradiography ex vivo and histological methoxy-
X04 staining (Table 1). Data from the three newly examined models was assessed using groups
of mice at different ages, while historical data from APPswe mice had been acquired longitudi-
nally. A total group of 22 age-matched C57Bl/6 mice (WT) served as control material. Details
of transgenic strains follow:
2.1.1 APPswe/PS2 (PS2APP). The transgenic B6.PS2APP (line B6.152H) is homozygous
for both the human presenilin (PS) 2, N141I mutant and the human APP K670N, M671L mu-
tant. APP and PS 2 transgenes are driven by mouse Thy-1 and mouse prion promoters, respec-
tively. This line had been created by co-injection of both transgenes into C57Bl/6 zygotes, as
previously described [14]. Homozygous B6.PS2APP mice were crossed with (C57Bl/6 x DBA/
2) x (C57Bl/6 x DBA/2) mice to generate the 152F2 mice, which are hemizygous for both trans-
genes, and show first plaques in the cortex and hippocampus at 6 months of age [15]. We
made PET recordings in 152F2 mice (N = 32), i.e. five animals aged five months, seven animals
aged eight months, six animals aged ten months, two aged 12 months, six aged 16 months and
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six aged 19 months; a subset was used for additional histological analysis. The six ten-month
old animals were used for test-retest experiments within an interval of one week.
2.1.2 APPswe/PS1G384A (G384A). APPswexPS1G384A mice were generated by crossing
of two pre-existing transgenic mouse lines. APPswe are characterized as stated above, while
PS1G384A carries a transgene for mutant PS 1 (G384A mutation; both lines are driven by a
Thy-1 promoter). G384A mice (carrying the APP23 transgene) accumulate a significant
amount of the 42 amino acid form of ß-amyloid (Aß42) by the time they are two months old;
amyloid plaques are at first sparsely distributed, and later on spread from deeper to superficial
cortical layers, with highest density in the frontal and somatosensory cortex [16]. We obtained
PET recordings in two animals aged five months, and a single animal aged 16 months.
2.1.3 APPswe/PS1dE9 (APP/PS1dE9). APP/PS1dE9 mice [17] overexpress the Swedish
mutation of APP, together with PS 1 deleted in exon 9 each driven by the mouse PrP promoter.
Overexpression of the transgene construct leads to overproduction of Swedish mutant APP
and the PS1 Δexon9 splice variant with concomitant increase in parenchymal β-amyloid load.
These mice develop the first plaques at four months of age mainly in cortical areas and the hip-
pocampus [18]. We obtained PET recordings from two mice aged 12 months and two animals
aged 24 months.
2.1.4 APPswe. Transgenic APPswe mice overexpressing human amyloid precursor protein
(APP) with the Swedish double mutation (K670N, M671L) driven by the mouse Thy1.2 pro-
moter were generated as described earlier [14]. These mice were backcrossed to C57BL/6 mice
Table 1. Overview of modalities assessed for the four AD mouse strains.
Mouse
Model
Age
(mo)
Gender
(f/m)
Amyloid
PET (N)
Methoxy-X04
Staining (N)
Ex Vivo
Autoradiography (N)
Amyloid PET
uncorrected
(SUVRCTX/CBL)
Amyloid PET PVE-
corrected (SUVRCTX/CBL)
PS2APP 5 m 5 0.95 ± 0.04 1.03 ± 0.08
8 m 7 1 1 1.04 ± 0.03* 1.23 ± 0.06*
10 m 6 1.07 ± 0.04** 1.38 ± 0.11***
12 m 2 2 2 1.12 / 1.24 1.47 / 1.55
16 m 6 1.28 ± 0.06*** 1.78 ± 0.16***
19 m 6 2 2 1.39 ± 0.09*** 2.08 ± 0.28***
G384A 5 f 2 2 0.93 / 0.98 1.05 / 1.13
16 f 1 1 1.11 1.42
APP/
PS1dE9
12 m 2 2 0.96 / 0.96 1.05 / 1.08
24 m 2 2 0.91 / 0.92 0.96 / 1.02
APPswe 10 m 5 0.94 ± 0.03 0.95 ± 0.04
13 f/m 12 2 0.94 ± 0.04 1.03 ± 0.08
16 f 8 1.00 ± 0.05* 1.15 ± 0.14**
20 f 5 8 1.09 ± 0.08*** 1.40 ± 0.23***
C57Bl/6 6–22 f 22 0.95 ± 0.03 0.98 ± 0.06
Column 4 indicates the number of animals assessed in PET examinations, whereas columns 5 and 6 indicate the number of hemispheres used for
histological and autoradiographic analyses. Uncorrected compared to PVE-corrected SUVRCTX/CBL for all studied groups of mice are provided in columns
7 and 8. mo = months, f = female, m = male. P-values for one-way ANOVA including post-hoc Tukey testing versus youngest littermates are given by:
* p < 0.05;
** p < 0.005;
*** p < 0.001.
Uncorrected SUVRCTX/CBL 95%-CI for pooled C57Bl/6 mice: 0.939–0.962.
doi:10.1371/journal.pone.0116678.t001
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to generate a line with less than 5% DBA2 background (as determined by microsatellites geno-
typing). Mice heterozygous for the transgene start to accumulate ß-amyloid at the age of ap-
proximately nine months and develop ß-amyloid plaques around the age of 12 months, mainly
in the cortical mantle. Historical PET data [3] from 15 APPswe mice imaged at four different
ages (10 months: N = 5; 13 months: N = 12; 16 months: N = 8; 20 months: N = 5) was repro-
cessed using the same standardized parameters as for the newly examined models.
2.2 Radiochemistry
The [18F]-florbetaben precursor (Piramal Imaging, Berlin) was radiolabeled by the method of
Zhang et al. [11], with slight modifications. This procedure yields a radiochemical purity ex-
ceeding 98% and specific activity of 50–90 GBq/μmol at the end of synthesis. In brief, [18F]fluo-
ride was produced by a cyclotron using the 18O(p,n)18F reaction and passed through a
Chromafix PS-HCO3 cartridge (Macherey-Nagel, Düren, Germany) as an aqueous solution in
[18O]-oxygen enriched water. The cartridge was dried with a stream of helium, and the [18F]-
activity eluted with 1 ml of Kryptofix 2.2.2 (K222)/K2CO3 solution (12.5 mg of K222 and 12.5 μl
of 1 M K2CO3 in CH3CN/H2O 0.8/0.2 mL). The solvent was removed at 90°C under a helium
stream, and the residue was azeotropically dried with 0.8 ml of anhydrous CH3CN twice at
90°C, followed by an additional drying in vacuo for five min. A solution of mesylate precursor
(5 mg) in anhydrous CH3CN (1 ml) was added to the reaction vessel containing the dried [
18F]
activity, and heated at 100°C for 12.5 min. Subsequently, HCl (2 M aqueous solution, 0.5 ml)
was added and the solution was stirred for another 7.5 min at 100°C. The solution was then
cooled to approximately 60°C and a solution containing 1.0 ml of 1 M NaOH and 2.0 ml of
0.1 M ammonium formate was added. The resultant slight cloudy solution was dissolved with
1.0–2.0 ml of CH3CN, and purified by HPLC using a Lichrosphere 100 RP18 semi-preperative
column (10×250 mm, 10 μm), with mobile phase consisting of CH3CN/ammonium formate
buffer (0.1 M, with 5 mg/mL sodium ascorbate) 60/40 delivered at a flow rate 5 ml/min. The
fraction with the desired product, which eluted with a retention time of 12 min, was collected
and diluted with 12 ml water containing 10 mg/ml sodium ascorbate. This solution was passed
through a Sep-Pak Light C18 cartridge and rinsed with 10 ml of 20% ethanol in water (also
containing 10 mg/ml sodium ascorbate) to separate the hydrolysis by-product from the [18F]
florbetaben final product, which was then eluted from the cartridge with 1–2 ml ethanol. For
mouse experiments, the eluate was divided into 100 μl portions, which were formulated with
900 μl of stabilization solution (1.78 ml PEG400, 6.72 ml H2O, 44 mg ascorbic acid, 288 mg so-
dium ascorbate), followed by adjustment of pH to 7.4 with 75 μl of concentrated phosphate
buffer (Braun, Melsungen, Germany). The total synthesis time was 75 min and radiochemical
yield was 18% (decay corrected). The product was examined for purity by analytical HPLC
using an XDB-C18 analytical column (150×4.6 mm, 5 μm; Agilent Technologies), and mobile
phase consisting of CH3CN/ammonium formate buffer (0.1 M, with 5 mg/mL sodium ascor-
bate) 60/40, delivered at a flow rate of 1 ml/min, giving a retention time of 6.2 min, as moni-
tored with serial UV and radiodetection.
2.3 Amyloid PET
Image acquisition and reconstruction followed a standardized protocol, with minor modifica-
tions from the previously-published methods [3]. Mice were anesthetized with isoflurane
(1.5%, delivered via a mask at 3.5 L/min in oxygen) and received bolus injection of 10.2 ±
2.1 MBq of [18F]-florbetaben in 150 μL of saline to a tail vein. Following placement in the
tomograph (Siemens Inveon DPET), a 15 min transmission scan was obtained using a rotating
[57Co] point source, followed by a single frame emission recording for the interval 30–60 min p.i..
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While still deeply anesthetized, mice were killed by cervical dislocation immediately after the PET
scan (62 min p.i.), followed by rapid removal of the brain (68 ± 4 min p.i.). The image reconstruc-
tion procedure consisted of a 3-dimensional ordered subset expectation maximization (OSEM)
with four iterations and 12 subsets followed by a maximum a posteriori (MAP) algorithm with 32
iterations. Scatter and attenuation correction were performed and a decay correction for [18F] was
applied. With a zoom factor of 1.0 and a 128 x 128 x 159 matrix, a final voxel dimension of 0.78 x
0.78 x 0.80 mmwas obtained. PET images were blinded to the reader by coding of the PET files.
Manual rigid-body co-registration of emission images to a 3T magnetic resonance imaging (MRI)
template, followed by manual rigid-body re-alignment of individual [18F]-florbetaben images on a
[18F]-florbetaben template was accomplished using the PMOD fusion tool (version 3.4; PMOD
Technologies Ltd.) [3]. The [18F]-florbetaben template had been generated previously by consecu-
tive dual tracer imaging with [18F]-FDG and [18F]-florbetaben.
For VOI-based analyses, a cerebellar VOI comprising 64 mm³, two bilateral frontal cortex
VOIs comprising 15 mm³ each and two bilateral hippocampal VOIs comprising 7mm³ each,
were employed for calculation of [18F]-florbetaben cortex-to-cerebellum (SUVRCTX/CBL) and
hippocampus-to-cerebellum standardized uptake value ratios (SUVRHIP/CBL). Cortical VOIs
were configured larger in comparison to the initial [18F]-florbetaben validation study [3] as
they proved higher robustness in a recent investigation [13]. The initial oval-shaped VOI was
superceded with an anatomically delineated VOI, more accurately accounting for the borders
of the neocortex.
Test-retest estimates were acquired in a subset of six PS2APP animals at ten months of age
within one week.
2.4 Partial volume effect correction
PVEC was first performed in a subset of five PS2APP animals for which ex vivo autoradiogra-
phy was available. After its successful validation, PVEC was applied to the entire dataset. In
particular, we used a VOI-based approach implemented in PMOD [19,20] with a full-width-
at-half-maximum (FWHM) of 1.72 mm, and a previously-evaluated VOI-mask for ten vol-
umes, consisting of two neocortical VOIs and one cerebellar VOI, along with further VOI
comprising the rest of the cerebrum, and an additional six extra-cerebral VOIs (Harderian
glands, frontal, superior, basal, spinal, and background). PVEC was additionally performed
using a VOI-mask including two hippocampal VOIs instead of the two neocortical VOIs [13].
The neocortical, hippocampal and cerebellar VOIs used for the VOI-mask were identical to
those used for calculation of the uncorrected PET data. As described by Rousset et al., regional
point spread functions were calculated through integration of single tissue domains’ point
spread function, and used for computation of weighting factors representing the contributions
of the set of ten tissue domains. Coefficients of a geometric transfer matrix (GTM) were calcu-
lated, and PVE-corrected radioactivity concentrations were calculated in the defined VOIs by
multiplication of the original PET data by the inverted GTM. The PVE-corrected images thus
contained only those regions with VOI-mask definitions, for comparison with VOI-based re-
sults for uncorrected PET data. Finally, VOIs were employed for calculation of PVE-corrected
[18F]-florbetaben cortex-to-cerebellum (SUVRCTX/CBL) and hippocampus-to-cerebellum
standardized uptake value ratios (SUVRHIP/CBL).
2.5 Ex vivo autoradiography
One hemisphere of five PS2APP animals (8 mo: N = 1; 12 mo: N = 2; 19 mo: N = 2) and of
one G384A mouse (16 mo: N = 1) killed at 62 min p.i. (Table 1) was frozen by immersion in
isopentane (-40°C); 20 μm thick sagittal slices were cut with a Leica CM 1510-1 Cryostat (Leica
Amyloid-PET in Transgenic ADMouse Models
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Microsystems, Nussloch Germany), and mounted on glass slides within 60 minutes post mor-
tem. An imaging plate (Fujifilm; BAS cassette2 2025) was exposed to the slides for ten hours,
scanned at 25 μm resolution with Raytest equipment (CR 35 BIO, Dürr Medical, Germany),
and analyzed with AIDA image analyzing software (V4.50). Cerebellar and frontal cortical
regions-of-interest (ROIs) were drawn analogous to PET-VOIs, and mean radioactivity concen-
trations per mg tissue equivalent were used for calculation of autoradiographic SUVRCTX/CBL
and SUVRHIP/CBL (mean of> 15 slices per animal). As a smaller cortical VOI was used in the
initial PET study of APPswe mice [3], we reanalyzed slices from the APPswe mice so as best to
match the approach used for the new material. Error-(%) in uncorrected and PVE-corrected
in vivo PET results was calculated relative to this high resolution “gold standard” of autoradio-
graphic results ex vivo.
2.6 Histochemical analyses
Cerebral hemispheres intended for histochemistry were fixed by immersion in 4% parafomal-
dehyde at 4°C for one week. Several representative 100 μm thick slices in the sagittal plane
about 1.5 mm from the midline were cut from each fixed hemisphere using a vibratome (VT
1000 S, Leica, Wetzlar, Germany). The slices were permeabilized overnight at room tempera-
ture in 2% Triton X-100 in phosphate buffered saline (PBS) at pH 7.4. Fibrillary ß-amyloid
plaques were stained with the fluorescent dye methoxy-X04 (0.01 mg/ml in PBS at pH 7.4 for
15 min) [21]. The unbound dye was removed by three washing steps with PBS, and the slices
were then mounted on microscope slides with fluorescent mounting medium (Dako, Ger-
many). 3D image stacks for each hemisphere were acquired on a confocal laser scanning mi-
croscope (LSM 780, Jena, Zeiss, Germany). Imaging of the whole slice was performed in tile
scan mode which allows automatic stitching of an array of fields of view. For this imaging, the
methoxy-X04 was excited at 405 nm, and the emitted light was collected from 410 to 585 nm.
The area and number of plaques were automatically counted using Imaris software (Imaris
7.4.2; Bitplane) in a region (0.49 ± 0.06 mm³) defined to match dimensions of the frontal cortex
VOI from PET image analysis. Plaque load was calculated as the summed area of all plaques
relative to the frontal cortex area. As a smaller cortical VOI was used in the initial PET study of
APPswe mice [3], we reanalyzed slices from the APPswe mice so as best to match the approach
used for the new material. The histological analyses were performed by an operator blind to
the PET results.
2.7 Statistics
Group comparisons of uncorrected and PVE-corrected VOI-based PET results measured as
SUVRCTX/CBL and SUVRHIP/CBL were performed using one-way ANOVA and the Tukey post-
hoc test for multiple comparisons, calculated by IBM SPSS 22 Statistics. Groups of APP-Swe
and PS2APP mice with N 5 were compared against their younger littermates and against the
WT group. Comparisons for groups with N< 5 were reported descriptively with their litter-
mates and respective WT animals. For correlation analyses and test-retest analyses, Pearson’s
coefficients of correlation (R) were calculated. A threshold of p< 0.05 was considered to be sig-
nificant for rejection of the null hypothesis.
2.8 Literature review
We performed a Pubmed search with the keywords “ADmouse model” and “amyloid PET” aim-
ing to identify all relevant studies. Mouse strain characteristics, the particular radiotracer, and
PET image acquisition and reconstruction parameters, as well as summary autoradiographic
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findings were recorded. Furthermore, Aß42/40 protein levels as well plaque load as functions of
mouse age were recorded, when available.
Results
3.1 Amyloid PET
3.1.1 Cortical findings. Compared to pooled WT animals (0.95 ± 0.03; 95%-CI: 0.939–0.962;
N = 22), PS2APP mice at an age of five months (N = 5) had a similar SUVRCTX/CBL (0.95 ±
0.04). PS2APP animals at eight months (N = 7) had an elevated SUVRCTX/CBL of 1.04 ± 0.03;
(+9%; p< 0.05), which further increased to 1.07 ± 0.04 (+12%; p< 0.005) at ten months (N =
6), 1.12/1.24 (+7/19%) at 12 months (N = 2), 1.28 ± 0.06 (+23%; p< 0.001) at 16 months (N =
6) and to 1.39 (+46%; p< 0.001) at 19 months (N = 6), when compared to their five month old
littermates. SUVRCTX/CBL results for PS2APP mice age 8 months differed significantly from
WT animals (p< 0.001). G384A mice at five months (N = 2) of age showed [18F]-florbetaben
SUVRCTX/CBL (0.93/0.98) comparable to that in WT mice; in the single 16 month old animal,
SUVRCTX/CBL had seemingly increased to 1.11 (+17%). The SUVRCTX/CBL of two APP/PS1dE9mice
scanned at 12months of age (0.96/0.96) was 5% lower in two littermates scanned at 24months of age
(0.91/0.92). Standardized re-analysis of the APPswemice showed an SUVRCTX/CBL of 0.94 ± 0.03
at 10 months of age (N = 5), which remained stable at 13 months (0.94 ± 0.04; N = 12) and then
increased to 1.00 ± 0.05 (+6%; p< 0.05) at 16 months (N = 8) and to 1.09 ± 0.08 (+16%; p< 0.001)
at 20 months (N = 5), when compared to their baseline (Fig. 1).
3.1.2 Hippocampal findings. SUVRHIP/CBL was 1.00 ± 0.03 in WTmice; corresponding
hippocampal measurements in PS2APP mice aged five, eight or ten months, G384A mice aged
five months, APP/PS1dE9 mice aged 12 and 24 months, and APPswe animals at 16 and 20
months were slightly higher than in WT, with SUVRHIP/CBL in the range of 1.04–1.08. Among
the PS2APP mice, significantly higher SUVRHIP/CBL values were observed in groups of six mice
aged 16 months (1.28 ± 0.07; p< 0.001) and aged 19 months (1.31 ± 0.12; p< 0.001) when
compared to their littermates at five months of age. Increased SUVRHIP/CBL was also seen in
the single 16 month old G384A mouse (1.13).
3.2 Partial volume effect correction and ex vivo autoradiography
Applying the PVEC increased the SUVRCTX/CBL measurements by 30 ± 11% (range: 12–53%)
in the five histologically analyzed PS2APP animals, with the more pronounced effect seen in
those animals with higher uncorrected SUVRCTX/CBL. Values of SUV in the cerebellum VOI in-
creased by 8 ± 4% with PVEC, propagating to a nonlinear relationship between PVE-corrected
and uncorrected SUVRCTX/CBL, which was described by y = 1.16x
1.65. Corrected SUVRCTX/CBL
was 1.18 in the single PS2APP mouse aged eight months and age-dependently increased to
1.47/1.55 (+25/31%) in the two mice aged 12 months and to 1.68/2.04 (+42/73%) in two mice
aged 19 months (Fig. 2A). Applying PVEC with the hippocampal VOI-mask increased
SUVRHIP/CBL by 20 ± 5%, in a nonlinear relationship described by y = 1.09x
1.34.
SUVRCTX/CBL by autoradiography ex vivo was 13–30% higher in PS2APP animals (1.18 at
eight months, 1.36/1.53 at 12 months, and 1.60/2.05 at 19 months) relative to PET results with-
out PVEC; this difference indicates an overall mean 22 ± 7% underestimation of amyloid bur-
den by PET. PVEC reduced this mean bias to a non-significant overestimation by 2 ± 5%
(Fig. 2B).
Autoradiographic SUVRHIP/CBL was 1.11 in an eight month old PS2APP animal, and
increased to 1.28/1.38 in two littermates aged 12 months and 1.27/1.55 in the pair aged
19 months. Uncorrected PET data showed a bias of −5 ± 4% versus +14 ± 12% with PVEC, in-
dicating increased bias and variance. SUVRCTX/CBL by autoradiography ex vivo in the single
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G384A mouse was 1.41, i.e. only 3% higher than the PVE-corrected PET SUVRCTX/CBL of 1.37,
and 29% higher than the uncorrected PET SUVRCTX/CBL of 1.09 in the right hemisphere.
3.3 PVEC application to the entire dataset
Uncorrected and PVE-corrected SUVRCTX/CBL of all mice are provided in Table 1. PVE-
corrected values distinctly increased the estimated slope, especially in the PS2APP strain and
the difference between young and old PS2APP animals (Fig. 3).
3.4 Test-retest
Uncorrected SUVRCTX/CBL was 1.07 ± 0.04 (range: 1.02–1.13) for the ten month old PS2APP
animals (N = 6) in the first PET session and 1.07 ± 0.03 (range: 1.04–1.12) when rescanned one
week later. PVE-corrected SUVRCTX/CBL results were 1.38 ± 0.11 (range: 1.20–1.48) in the first
Figure 1. Multi-modal analysis of the four ADmouse strains studies in this cross-sectional [18F]-florbetaben PET study.Upper images represent
group averaged sagittal PET slices, normalised to the cerebellum and overlayed on an MRI mouse atlas [39]. Dots indicate corresponding assessments of
SUVRCTX/CBL in individual mice. Dashed lines express the estimated time dependent progression in PS2APP (red; five months: N = 5; eight months: N = 7;
10 months: N = 6; 12 months: N = 2; 16 months: N = 6, 19 months: N = 6), G384A (green; five months: N = 2; 16 months: N = 1) and APP/PS1dE9 (purple; 12
months: N = 2; 24 months: N = 2) mice, fitted with a polynomial function (for the purposes of illustration). Longitudinal progression in APPswe mice is
indicated by a continuous blue line. Lower images depict representative ex vivo autoradiography results; autoradiography of APP/PS1dE9 mice and young
G384Amice was performed in vitro. WT level expresses the mean SUVRCTX/CBL of pooledWTmice (N = 22).
doi:10.1371/journal.pone.0116678.g001
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scan and 1.39 ± 0.09 (range: 1.23–1.51) in the rescan. Correlation analysis between individual
test and re-test results gave R = 0.90 (p< 0.05) for uncorrected and R = 0.94 (p< 0.005) for
PVE-corrected data.
3.5 Histochemical analyses
3.5.1 Plaque analysis. PS2APP mice had close to 1300 mainly compact plaques in the frontal
cortex at all ages studied, but the average size and maximum plaque diameter increased with,
leading to a plaque load of up to 12.2% in 19 month old animals; plaques were also abundant
in olfactory bulb and thalamus. G384A mice showed a fourfold increase in number of plaques
from 5 to 16 months of age, with a concomitant increase in mean diameter. APP/PS1dE9 mice
revealed a sparse distribution of small plaques in cerebral cortex, and also in cerebellum. Re-
analysis of material from APPswe mice aged 20 months showed distinctly larger plaques (max.
diameter 243 μm) compared to the three other strains (all< 100 μm). Plaque load in 20 month
old APPswe mice (6.3 ± 3.1%) was comparable to that of the 16 month old G384A mouse
(7.6%). For details see Table 2.
3.5.2 Cross-sectional plaque load correlation. We found a very high correlation between
cortical plaque load in all 22 hemispheres stained with methoxy-X04 and the uncorrected
SUVRCTX/CBL (R = 0.94, p< 0.001; Fig. 4A) as well as with the PVE-corrected SUVRCTX/CBL
(R = 0.95, p< 0.001; Fig. 4B) as assessed by [18F]-florbetaben PET. The only outlier was a single
24 month old APP/PS1dE9 mouse (arrow), in which too low SUVRCTX/CBL was apparently due
to bias in PET results arising from plaques in the cerebellum reference region.
Figure 2. Amyloid-PET and ex vivo autoradiography in PS2APPmice before and after PVEC. (A) Comparison of uncorrected [18F]-florbetaben PET
images (upper row), corresponding ex vivo autoradiography (mid row) and PVE-corrected PET (lower row) of representative PS2APPmice at 8, 12 and 19
months of age. Sagittal PET images captured 1.6 mm left of the midline were scaled to cerebellum and overlain on a 3T MRI mouse template [13]. PVEC was
performed with a 10 region mask (four cerebral and six extracerebral VOIs). (B) Error-(%) (±SD) of uncorrected (black bar) and PVE-corrected (blue bar) data
versus ex vivo autoradiography are shown for the whole group of PS2APPmice.
doi:10.1371/journal.pone.0116678.g002
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Discussion and Review of the Literature
We present the first cross-sectional small animal PET study with a single [18F]-labelled radio-
tracer for β-amyloid under uniform standardized experimental settings in several established
AD mouse models. We found distinct differences in time course and anatomic pattern of β-
amyloid deposition among the four AD mouse strains investigated. PET findings of cortical
[18F]-florbetaben binding in AD mouse models matched precisely the distribution of plaques
verified by histology with methoxy-X04 staining. Of the four AD mouse strains examined,
PS2APP mice were judged most suitable for future intervention studies, based on the presence
of [18F]-florbetaben binding in mice aged only 8 months, continued substantial β-amyloid
accumulation to at least 19 months, and lack of specific binding in the cerebellum reference
region.
4.1 PS2APP animals
A previous study with [18F]-florbetapir in double transgenic APP/PS1 mice showed an increas-
ing PET signal from three to five months, but no further progression to 12 months [6]; the
transgenic animals attained a constant SUVRCTX/CBL for [
18F]-florbetapir of only 1.1. This PET
finding was in contrast to histopathological plaque load, which increased 3-fold from four to
eight months of age, and further doubled by 19 months of age [22]. In contrast, our PS2APP
mice showed 8% elevated [18F]-florbetaben SUVRCTX/CBL at eight months relative to WT mice,
and then a continuous progression of cortical binding to 19 months. The PET findings are in
line with histology, and with earlier reports of β-amyloid protein levels in the PS2APP strain
[15]. Compared to the human pathology compact plaques of different sizes represent the ma-
jority in old PS2APP mice, whereas diffuse and cored plaques are predominating in AD pa-
tients [23]. Similarly there was general agreement between PET signal from [11C]-Pittsburgh
Compound B ([11C]-PiB), plaque load and Aß42 protein in homozygous ARTE 10 mice, which
Figure 3. Comparison of uncorrected (A) and PVE-corrected (B) SUVRCTX/CBL of the entire dataset.Dots indicate corresponding assessments of
SUVRCTX/CBL in individual mice. Dashed lines express the estimated time dependent progression in PS2APP (red; five months: N = 5; eight months: N = 7;
10 months: N = 6; 12 months: N = 2; 16 months: N = 6, 19 months: N = 6), G384A (green; five months: N = 2; 16 months: N = 1) and APP/PS1dE9 (purple;
12 months: N = 2; 24 months: N = 2) mice, fitted with a polynomial function (for the purposes of illustration). Longitudinal progression in APPswemice is
indicated by a continuous blue line. P-values for one-way ANOVA (incl. post hoc Tukey) testing of PS2APP and APPswe mice versus youngest littermates
were as indicated: * p< 0.05; ** p< 0.005; *** p< 0.001.
doi:10.1371/journal.pone.0116678.g003
Table 2. Comparison of histological results obtained from the four different AD mouse strains (columns 1–3).
Mouse Model Age (mo) N Plaque Load (PL-%) Plaque Count (N) Plaque Density (N/mm3)
PS2APP 8 1 4.9 1408 2930
PS2APP 12 2 8.5 / 10.2 1496 / 1402 4121 / 3762
PS2APP 19 2 9.6 / 12.2 1281 / 1460 2982 / 2936
G384A 5.5 2 0.8 / 2.2 209 / 477 346 / 852
G384A 16 1 7.6 1216 2866
APP/PS1dE9 12 2 1.8 / 2.0 599 / 522 1256 / 1185
APP/PS1dE9 24 2 2.0 / 4.2 361 / 839 731 / 1862
APPswe 20 5 6.3 ± 3.1 349 ± 105 715 ± 244
Plaque load percentage (PL-%) and plaque numbers in the frontal cortex VOI are reported (columns 4 and 5), as well as the density of plaques (column
6). Exempliﬁed sagittal slices from methoxy-X04 staining of ß-amyloid plaques are shown together with illustrations of the plaque size distribution in S1
Table.
doi:10.1371/journal.pone.0116678.t002
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were evaluated at ages up to 21 months [4]. A recent report of 5xFAD mice examined with
[11C]-PiB and [18F]-florbetapir at 11 months of age showed distinctly elevated cortical uptake
of both tracers (+20%) compared to WT mice [8]. Thus, the report of a plateau of [18F]-
florbetapir uptake in aging APP/PS1 mice may be anomalous.
4.2 G384A animals
Double transgenic mice carrying mutations of APP and the G384A mutation are reported to
develop solid amyloid plaques as early as two months of age, when the APP23 strain was used
for the cross-breeding [16]. In our study methoxy-X04 staining revealed solid plaques at a low
plaque load of 1.5% in G384A mice aged five months including the APPswe mutation. Howev-
er we did not see consistently elevated [18F]-florbetaben PET signal in these animals, but only
in a single mouse aged 16 months which presented a 5-fold higher plaque load compared to
five months. We concede that we examined relatively few G384A mice, i.e. two animals at
5 months and a single animal aged 16 months. As the extent of amyloidosis in transgenic AD
models can be highly variable, the seeming increase in the single G384A mouse has to be inter-
preted with caution. Nonetheless, the evidence for a positive ß-amyloid PET signal was unam-
biguous in the aged animal of this strain, as its signal clearly exceeded the upper bound of the
95%-CI in WTmice.
There is abundant precedent in the literature for discrepancies between age of plaque onset
and detectability with small animal amyloid PET. Thus, several explorations of APP23 mice
imaged with [11C]-PiB [7,24,25] showed that transgenic mice with only an APP mutation can
indeed serve for β-amyloid imaging. Sparse plaque formation was evident histologically in
APP23 mice as early as six months, and aged animals exhibited numerous large dense-core pla-
ques, high Aß40 level and a remarkable plaque load (Table 3). Nonetheless, elevated [11C]-PiB
Figure 4. Cross-sectional correlation of plaque load percentage (methoxy-X04 staining) with uncorrected (R = 0.94; p< 0.001) (A) and PVE-
corrected (R = 0.95; p< 0.001) (B) [18F]-florbetaben PET results (SUVRCTX/CBL) for PS2APP (red squares; eight months: N = 1; 12 months: N = 2; 19
months: N = 2), G384A (green diamonds; five months: N = 2; 16 months: N = 1), APP/PS1dE9 (purple triangle; 12 months: N = 2; 24 months: N = 2)
and APPswe (blue circles; 13 months: N = 2; 20 months: N = 8) mice. A total of 22 hemispheres from 19 animals were examined by histology. Black
arrow depicts an APP/PS1dE9 mouse with extensive cerebellar plaque load, which resulted in an anomalously low PET SUVRCTX/CBL.
doi:10.1371/journal.pone.0116678.g004
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PET signal was first seen at 15 months of age. Similarly, we have reported low [18F]-florbetaben
SUVRCTX/CBL in APPswe animals aged ten months, even though histological plaque formation
is already established at nine months. Indeed, our 13 month old mouse with histologically de-
tectable plaques did not show a discernibly elevated PET signal. We have earlier calculated,
based upon the concordance of PET signal and histology that the [18F]-florbetaben PET meth-
od was sensitive for a 1.5% plaque load in APPswe mice [3]. This sensitivity limit, which likely
accounts for the temporal gap between onset of pathology and detection threshold by PET,
must be determined for each strain in order to anticipate the statistical power of treatment
studies, especially for AD models without acceleration of amyloidosis due to a presenilin
mutation.
Protein levels of ß-amyloid of 42 amino acid length (Aß42), ratio of ß-amyloid 42 to 40
(Aß42/40) and cortical plaque load percentage (PL-%) were compared for mice of different
ages (column 1). Protein levels are given in ng protein/mg wet brain weight. N.b; calculations
of PL-% were obtained using various techniques, and are therefore only approximately compa-
rable between studies. Conversion factors used to aid this comparison were: Aß40: 4330 g/mol;
Aß42: 4514 g/mol; total protein (g) per wet brain (g) = 9.4/100.
4.3 APP/PS1dE9 animals
From our data in four mice, the APP/PS1dE9 model appeared unsuitable for PET quantitation of
relative cerebral amyloid burden due to the presence of ß-amyloid pathology in the reference re-
gion (cerebellum). Furthermore, cortical plaque levels in even the most aged mice (24 mo) only
slightly exceeded our detection threshold for [18F]-florbetaben PET (noted above), with the cave-
at that one must take into the small sample size. In concordance with this finding in vivo, the
plaque load (Table 2) and Aß42 protein levels (Table 3) in the APP/PS1dE9 strain appear far
lower than those of APP23, G384A and PS2APP mice, which likely accounts for the lower [18F]-
florbetaben PET signal in 24 month old APP/PS1dE9 mice when compared to other mouse
strains at this age. Earlier reports on APP/PS1dE9 mice did not report the presence of cerebellar
plaques, albeit these studies were confined to younger animals [17,26], or only investigated fore-
brain for histological analyses [27]. However, a very recent longitudinal [11C]-PiB PET study of
APP/PS1dE9 mice reported cerebellar plaques in 19 month old mice [7]. In our hands, aged
APP/PS1dE9 mice had comparable ß-amyloid levels in cerebellum and in cortical areas, such
that the SUVRCTX/CBL actually declined from 12 to 24 months of age, ultimately falling below the
lower bound of the 95%-CI inWTmice. The cerebellum has been used as a reference region in
nearly all recent small animal β-amyloid PET studies, although its histological suitability was pre-
viously established only for ARTE 10 and APPswe mice [3,4]. The plaque-free pons might be
proposed as an alternate reference region, but due to its small size in mice, we expect that its use
would bring considerable penalty in precision of binding ratios. Furthermore, plaques in APP/
PS1dE9 mice had 3-fold higher plaque area in a 3D6-immunohistochemistry study which also
detects diffuse β-amyloid deposits, in contrast to thioflavin S staining, which is only sensitive to
dense aggregates [26]. Our approach of using a radiotracer and a histological marker with similar
binding characteristics gave more concordant results, in that low plaque load matched with low
in vivo [18F]-florbetaben binding. Therefore, we agree with Snellman et al. (2013) that low
SUVRCTX/CBL magnitude likewise reflected inherently lower radiotracer binding in 24 month old
APP/PS1dE9 mice when compared to other ADmouse strains at this age.
4.4 Partial volume effect correction
A previous report on [18F]-florbetapir PET in APP/PS1 mice reported 20–30% higher
SUVRCTX/CBL in autoradiographic results ex vivo compared to PET findings [6]. We likewise
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found nearly identical discrepancies by method in young and aged PS2APP animals, as well as
the re-evaluated APPswe mice, which we attribute to errors in regional quantitation arising
from uncorrected PVEs. Application of the Rousset method for cross-talk correction essentially
removed the bias in our PET estimates [13]. The present generalization of the PVEC algorithm
to another mouse model helps establish the validity of the approach to improved quantitation;
there have been but few investigations of PVEC in the rodent brain. We find that cortical spill-
over is otherwise a significant factor in underestimating β-amyloid signal, especially in mice
with high plaque load. The systematic use of PVEC will help to reduce quantification bias in
future studies, and should improve sensitivity of PET for detecting effects of interventions. Un-
like in neocortex, uncorrected PET results in hippocampus were more congruent with the au-
toradiographic results, no doubt due to the VOI being surrounded by tissues with similar
radioactivity concentrations, resulting in lesser net spill-out of signal. Indeed, PVEC for hippo-
campus resulted in overcorrection and excessive variance, which is unsurprising for such small
structures (6.6 mm³). Despite the limitations of PVEC for the mouse hippocampus, in vivo
β-amyloid imaging of that structure may yet be possible without correction, as suggested by
our finding of increasing SUVRHIP/CBL in aged PS2APP animals.
4.5 Cross-sectional plaque load correlation
The reason for the general finding of low binding of β-amyloid PET radiotracers in the brains
of young transgenic mouse models of AD, or even absence of specific signal in some strains, de-
spite abundant β-amyloid levels, is a matter of considerable controversy. Maeda et al. [25] even
reported lower in vitro binding of [11C]-PiB to plaques in double transgenic PS-1/APP mice
aged eight months compared to Tg2576 animals aged 23 months with similar Aß42 levels; they
concluded that plaque formation in accelerated models impart fewer radiotracer binding sites
due to post-translation factors resulting in lower AßN3-pyroglutamate composition. We found
an excellent cross-sectional correlation of PET results and methoxy-X04 staining for our four
AD models (Fig. 4). This probably reflects the similar binding/staining properties of [18F]-flor-
betaben and methoxy-X04, as both detect fibrillar but not diffuse β-amyloid depositions
[10,21]. Although different mouse strains in this investigation had a high variability of plaque
sizes, numbers and morphology, the relationship between stained fibrillar β-amyloid intensity
and radiotracer binding was nearly linear. Of note is that in cortex of AD patients the compact
plaque type occurs at only 10%, with cored and diffuse plaques dominating. Furthermore all
three plaque types differ with respect to Aβ species, with diffuse and compact plaques contain-
ing mostly Aβ42, while cored plaques contain Aβ40 [23].
We conclude that histological analyses with this Congo red derivate are indeed predictive of
[18F]-florbetaben binding sites to be imaged by PET, with the caveat that the in vivomethod is
insensitive to low plaque loads (<1.5%). This is probably related to factors such as low specific
binding signal, the limited spatial resolution of PET, and image noise. Additionally, the impact
of different specific activities of [18F]-florbetaben have not yet been tested systematically in pre-
clinical settings, and might conceivably have influenced the detectability threshold in our study
[25], however in a preliminary analysis in a series of PS2APP mice no conspicuous effect on
scan results as a function of time from end of synthesis could be observed (data not shown).
Comparisons between β-amyloid PET studies in AD mouse models must be made with
some caution, due to diverse methodological differences, including the particular radiotracers,
emission recording time-frames and reconstruction parameters. Cortex-to-reference region es-
timates for WT animals fall within a narrow range in a number of recent small animal PET
studies using different radiotracers irrespective of age (Table 4), which predicts general stabili-
ty of the method. On the other hand, PET signals in transgenic animals are more difficult to
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Table 4. Comprehensive overview of small animal β-amyloid PET studies in transgenic AD mice.
Mouse
Model /
Study
Age
(mo)
N Radiotracer Activity
(MBq)
Scanner Reconstr. SC AT M Voxel
size
(mm3)
EM
time
(min
p.i.)
PET:
SUVRCTX/CBL
PET:
cortical
BPND
Corresp.
PET of
WT
SUVR or
BPND
Ex vivo
Autorad.
SUVRCTX/CBL
Tg2576
[37]
22 6 [11C]-PiB 13–46 NIH 3D OSEM x x x 0.6 x
0.6 x
1.1
12–30 1.06 ± 0.04 0.98 ±
0.07
Tg2576
[5]
14 6 [18F]-
FDDNP
4–10 F220 FORE,
2D FBP
x o x n.r. 0–60 0.92 ± 0.10 1.00 ±
0.09
Tg2576
[7]
9 3 [11C]-PiB 8.7 ±
1.4
Inveon FORE,
2D FBP
o o x 0.8 x
0.8 x
0.8
5–60 0.97 ±
0.06**
12 2 [11C]-PiB 8.7 ±
1.4
Inveon FORE,
2D FBP
o o x 0.8 x
0.8 x
0.8
5–60 0.95 ±
0.04**
19 2 [11C]-PiB 8.7 ±
1.4
Inveon FORE,
2D FBP
o o x 0.8 x
0.8 x
0.8
5–60 1.06 ±
0.04**
22 2 [11C]-PiB 8.7 ±
1.4
Inveon FORE,
2D FBP
o o x 0.8 x
0.8 x
0.8
5–60 1.02 ±
0.08**
1.04 ±
0.01**
APP23
[25]
21.4 11 [11C]-PiB 30 ± 6.8 F220 FORE,
2D FBP
x o x n.r. 0–60 0.30 ±
0.04
0.00 ±
0.01
3.2 ± 0.6
17 5 [11C]-PiB 31 ± 6.8 F220 FORE,
2D FBP
x o x n.r. 0–60 0.06
22 5 [11C]-PiB 30 ± 6.8 F220 FORE,
2D FBP
x o x n.r. 0–60 0.36
27 5 [11C]-PiB 31 ± 6.8 F220 FORE,
2D FBP
x o x n.r. 0–60 0.64
APP23
[24]
22.6 12 [11C]-PiB 30.3 ±
5.5
F220 FORE,
2D FBP
x o x n.r. 0–60 0.31 ±
0.05
APP23
[7]
7 2 [11C]-PiB 8.7 ±
1.4
Inveon FORE,
2D FBP
o o x 0.8 x
0.8 x
0.8
5–60 1.02 ±
0.07**
12 2 [11C]-PiB 8.7 ±
1.4
Inveon FORE,
2D FBP
o o x 0.8 x
0.8 x
0.8
5–60 0.98 ±
0.07**
15 1 [11C]-PiB 8.7 ±
1.4
Inveon FORE,
2D FBP
o o x 0.8 x
0.8 x
0.8
5–60 1.19**
18 3 [11C]-PiB 8.7 ±
1.4
Inveon FORE,
2D FBP
o o x 0.8 x
0.8 x
0.8
5–60 1.38 ±
0.03**
21 1 [11C]-PiB 8.7 ±
1.4
Inveon FORE,
2D FBP
o o x 0.8 x
0.8 x
0.8
5–60 1.34** 1.08 ±
0.02**
APP/
PS1-21
[6]
3 5 [18F]-
Florbetapir
10–15 Inveon FORE,
2D OSEM
x o x 0.4 x
0.4 x
0.8
30–60 1.01 1.00 1.30
5 5 [18F]-
Florbetapir
10–15 Inveon FORE,
2D OSEM
x o x 0.4 x
0.4 x
0.8
30–60 1.11 1.01
8 5 [18F]-
Florbetapir
10–15 Inveon FORE,
2D OSEM
x o x 0.4 x
0.4 x
0.8
30–60 1.06 0.97 1.61
(Continued)
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Table 4. (Continued)
Mouse
Model /
Study
Age
(mo)
N Radiotracer Activity
(MBq)
Scanner Reconstr. SC AT M Voxel
size
(mm3)
EM
time
(min
p.i.)
PET:
SUVRCTX/CBL
PET:
cortical
BPND
Corresp.
PET of
WT
SUVR or
BPND
Ex vivo
Autorad.
SUVRCTX/CBL
12 5 [18F]-
Florbetapir
10–15 Inveon FORE,
2D OSEM
x o x 0.4 x
0.4 x
0.8
30–60 1.09 0.96 1.65
ARTE 10
(tg) [38]
24.6 18 [11C]-PiB 20.2 ±
5.6
F120 FORE,
2D FBP
x o o 0.8 x
0.8 x
0.8
36–45 1.26 ± 0.15*
ARTE 10
(tg) [4]
23.2 5 [11C]-PiB 13.9 F120 FORE,
2D FBP
x o o 0.9 x
0.9 x
0.8
0–60 0.28 ±
0.06
−0.10 ±
0.03
1.90 ± 0.26
(tg-tg) 9.2 7 [11C]-PiB 45.2 F120 FORE,
2D FBP
x o o 0.9 x
0.9 x
0.8
0–60 0.12 ±
0.03
−0.10 ±
0.03
1.25 ± 0.07
(tg-tg) 21.1 4 [11C]-PiB 22.4 F120 FORE,
2D FBP
x o o 0.9 x
0.9 x
0.8
0–60 0.51 ±
0.13
−0.10 ±
0.03
2.54 ± 0.27
APP/
PS1dE9
[7]
9 2 [11C]-PiB 8.7 ±
1.4
Inveon FORE,
2D FBP
o o x 0.8 x
0.8 x
0.8
5–60 1.03 ±
0.06**
12 2 [11C]-PiB 8.7 ±
1.4
Inveon FORE,
2D FBP
o o x 0.8 x
0.8 x
0.8
5–60 1.07 ±
0.04**
15 2 [11C]-PiB 8.7 ±
1.4
Inveon FORE,
2D FBP
o o x 0.8 x
0.8 x
0.8
5–60 ±
0.04**
19 2 [11C]-PiB 8.7 ±
1.4
Inveon FORE,
2D FBP
o o x 0.8 x
0.8 x
0.8
5–60 0.98 ±
0.03**
1.01 ±
0.02**
APP/
PS1dE9
(this
paper)
12 2 [18F]-
Florbetaben
10.2 ±
2.1
Inveon 3D
OSEM,
MAP
o o x 0.8 x
0.8 x
0.8
30–60 0.96 / 0.96 0.96 ±
0.02
24 2 [18F]-
Florbetaben
10.2 ±
2.1
Inveon 3D
OSEM,
MAP
o o x 0.8 x
0.8 x
0.8
30–60 0.91 / 0.92 0.96 ±
0.03
5xFAD
[8]
11.2 10 [18F]-
Florbetapir
9.3 ±
3.4
R4 n.r. x x x n.r. 45–75 1.19 ± 0.02* 1.03 ±
0.02*
10.5 10 [11C]-PiB 11.5 ±
3.6
R4 n.r. x x x n.r. 35–65 1.21 ± 0.04* 1.00 ±
0.03*
G384A
(this
paper)
5.5 2 [18F]-
Florbetaben
10.2 ±
2.1
Inveon 3D
OSEM,
MAP
o o x 0.8 x
0.8 x
0.8
30–60 0.93 / 0.98 0.99 ±
0.03
16 1 [18F]-
Florbetaben
10.2 ±
2.1
Inveon 3D
OSEM,
MAP
o o x 0.8 x
0.8 x
0.8
30–60 1.11 0.96 ±
0.02
1.41
APPswe
[3]
10 5 [18F]-
Florbetaben
8.9 ±
2.7
Inveon 3D
OSEM,
MAP
o o x 0.8 x
0.8 x
0.8
30–60 0.94 ± 0.03 0.96 ±
0.02
13 10 [18F]-
Florbetaben
8.9 ±
2.7
Inveon 3D
OSEM,
MAP
o o x 0.8 x
0.8 x
0.8
30–60 0.94 ± 0.04 0.95 ±
0.02
1.01 ± 0.04
(Continued)
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compare, as sizes and anatomic compositions of target VOIs, i.e. forebrain, entire cortex, or
hot spot, greatly influence PET quantification. In published studies, APP23, ARTE 10, APPswe,
PS2APP, and G384A mice have all been found to meet criteria for PET monitored treatment
studies, whereas Tg2576, APP/PS1-21 and APP/PS1dE9 animals lacked sufficient or longitudi-
nal increases of the PET signal. Limited evidence also supports the use of 5xFAD mice for
longitudinal studies.
4.6 Protein quantification and plaque load
Based on our literature review, high Aß42 protein levels (> 100 ng/mg wet brain) have been
found in APP23, G384A, PS2APP, ARTE10 and 5xFADmice, even at ages less than 12 months
in the latter four strains (Table 3). In contrast, Tg2576, APPswe, and APP/PS1dE9 mice had far
Table 4. (Continued)
Mouse
Model /
Study
Age
(mo)
N Radiotracer Activity
(MBq)
Scanner Reconstr. SC AT M Voxel
size
(mm3)
EM
time
(min
p.i.)
PET:
SUVRCTX/CBL
PET:
cortical
BPND
Corresp.
PET of
WT
SUVR or
BPND
Ex vivo
Autorad.
SUVRCTX/CBL
16 8 [18F]-
Florbetaben
8.9 ±
2.7
Inveon 3D
OSEM,
MAP
o o x 0.8 x
0.8 x
0.8
30–60 1.00 ± 0.05 0.96 ±
0.02
20 5 [18F]-
Florbetaben
8.9 ±
2.7
Inveon 3D
OSEM,
MAP
o o x 0.8 x
0.8 x
0.8
30–60 1.09 ± 0.08 0.96 ±
0.01
1.48 ± 0.19
PS2APP
(this
paper)
5 5 [18F]-
Florbetaben
10.8 ±
1.7
Inveon 3D
OSEM,
MAP
o o x 0.8 x
0.8 x
0.8
30–60 0.95 ± 0.04 0.99 ±
0.03
8 7 [18F]-
Florbetaben
10.5 ±
1.6
Inveon 3D
OSEM,
MAP
o o x 0.8 x
0.8 x
0.8
30–60 1.04 ± 0.03 0.98 ±
0.03
1.18
10 6 [18F]-
Florbetaben
11.4 ±
1.3
Inveon 3D
OSEM,
MAP
o o x 0.8 x
0.8 x
0.8
30–60 1.07 ± 0.04 0.96 ±
0.03
12 2 [18F]-
Florbetaben
10.2 ±
2.1
Inveon 3D
OSEM,
MAP
o o x 0.8 x
0.8 x
0.8
30–60 1.12 / 1.24 0.96 ±
0.02
1.36 / 1.53
16 6 [18F]-
Florbetaben
10.8 ±
2.5
Inveon 3D
OSEM,
MAP
o o x 0.8 x
0.8 x
0.8
30–60 1.28 ± 0.06 0.97 ±
0.03
19 6 [18F]-
Florbetaben
10.2 ±
2.1
Inveon 3D
OSEM,
MAP
o o x 0.8 x
0.8 x
0.8
30–60 1.39 ± 0.09 0.95 ±
0.04
1.60 / 2.05
Results of eleven published studies using eight different strains at multiple ages (columns 1–3) were compared for particular tracer (columns 4–5), PET
instrumentation (column 6) acquisition and reconstruction parameters (columns 7–12), PET results (columns 13–15) and autoradiographic results ex vivo
(column 16).
* indicates whole forebrain instead of a cortical VOI.
** indicates the distribution volume ratio (DVR), equal to the binding potential (BPND) plus one. 2/3D = two/three-dimensional, EM = emission, MAP =
maximum a posteriori, OSEM = ordered subset expectation maximization, FORE = Fourier rebinning, FBP = ﬁltered back projection, o = used, x =
missing, n.r. = not reported, p.i. = post injection, tg = transgenic, SC = scatter correction, AT = attenuation correction, M = motion correction, [11C]-PiB =
[11C]-Pittsburgh Compound B, [18F]-FDDNP = 2-(1-(6-[(2-18F-ﬂuoroethyl)(methyl)amino]-2-naphthyl)ethylidene)-malononitrile. PET Scanners: NIH = NIH
Advanced Technology Laboratory Animal Scanner (ATLAS); F120/220 = Micro-PET Focus 120/220 Animal Scanner (Siemens Medical Solutions USA,
Knoxville, TN); Inveon = Preclinical Inveon PET (Siemens Medical Solutions USA, Knoxville, TN); R4 = Concorde Microsystems microPET R4.
doi:10.1371/journal.pone.0116678.t004
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less protein accumulation, even in aged animals. In animals for which plaque load measurements
were also available, there was a close correspondence between histological load and Aß42 protein
levels. Aß42 concentration in APP/PS1-21 mice increased from 11 ng/mg wet brain at three
months of age to 67 ng/mg wet brain at eight months of age, and was not assessed at greater ages,
whereas the histological plaque load in these animals further doubled at 19 months of age. Pro-
tein levels and plaque load results derive from different publications using a variety of methodol-
ogies for the assessment. Comparisons between different mouse strains should therefore be made
with some caution.
4.7 Limitations
The findings reported for G384A and APP/PS1dE9 mice are qualified by the small sample size
per time point in these strains. Further PET scans could not be obtained in these strains due to
unavailability of additional mice.
Conclusion
Present findings support the use of double transgenic PS2APP mice for early detection of
cortical β-amyloid deposition by means of [18F]-florbetaben PET, in conjunction with PVEC.
Uniform standardized procedures offer the capability for valid comparisons of β-amyloid
PET results in different AD mouse strains. Interpretation of PET results in specific models is
facilitated in a cross-sectional context, which removes most sources of differences between
studies. The question if single or multi transgenic models are better suited for future treatment
approaches likely depends on the type of intervention to be tested.
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